We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

CELLAVISION AB

First Leukemia Diagnostic Test Based on DNA Sequencing Detects up To 51 Gene Mutations

By LabMedica International staff writers
Posted on 02 Jan 2023

Until recently, a series of blood tests and a bone marrow biopsy were required when someone was "suspected" to have leukemia. It costs thousands of dollars and takes somewhere between six and nine weeks for a diagnosis. In addition to being time consuming, it is a subjective interpretation as cytology remains dependent on human interpretation. Until 2022 the only leukemia tests done could detect two gene mutations. Now, a new leukemia diagnostic test is capable of detecting 51 gene mutations, marking a significant technological and medical advancement.

Alercell, Inc. (Bozeman, MT, USA) is all set to launch LENA Q51(R) in January 2023. LENA Q51 is a leukemia diagnostic test based on sequencing DNA and can detect up to 51 gene alterations in leukemia patients. With LENA Q51, clinicians using a qPCR machine will be able to identify any gene mutations among 51 different genes in just three hours. By doing this, clinicians can determine the gene mutations in three hours via computer, eliminating the need for human interpretation. The information gathered will also enable clinicians to tailor the patient's treatment - all of this at a much lower cost. Alercell also plans to launch LENA S1, the first methylation-based molecular diagnostic test for lung cancer, in the first quarter of 2023. As an epigenetic regulator of gene expression, DNA methylation enables early diagnosis of lung cancer and very accurate localization of the disease, if present.


Image: The Lena Q51 leukemia diagnostic test will be launched in January 2023 (Photo courtesy of Alercell)
Image: The Lena Q51 leukemia diagnostic test will be launched in January 2023 (Photo courtesy of Alercell)

"I am thrilled that via the application of our knowledge of the genome, we are now able to produce very performing tests that will help people in finally avoiding the unpleasant traditional treatment," said Alercell co-founder Frederic Scheer.

Related Links:
Alercell, Inc.


New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Latest Hematology News

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy



LGC Clinical Diagnostics